JW Lifescience KRX:234080KOSPI
JW생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, JW Lifescience reported revenue of ₩63.2bn, up 1.6% year on year, and operating profit of ₩9.3bn. JW Lifescience (JW생명과학) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
JW Lifescience quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩63.2bn | +1.6% | ₩9.3bn margin 14.8% | ₩8.0bn |
| Q1 2026 | ₩63.5bn | -7.4% | ₩9.3bn margin 14.7% | ₩6.7bn |
| Q4 2025 derived | ₩64.3bn | +17.4% | ₩7.6bn margin 11.8% | ₩6.5bn |
| Q3 2025 | ₩62.6bn | +8.0% | ₩7.1bn margin 11.3% | ₩4.9bn |
| Q2 2025 | ₩62.3bn | +14.5% | ₩9.4bn margin 15.1% | ₩11.2bn |
| Q1 2025 | ₩68.6bn | +24.0% | ₩9.2bn margin 13.4% | ₩6.1bn |
| Q4 2024 derived | ₩54.8bn | +2.2% | ₩9.6bn margin 17.5% | ₩25.4bn |
| Q3 2024 | ₩58.0bn | +13.3% | ₩9.3bn margin 16.0% | ₩6.8bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
JW Lifescience top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest JW Lifescience news Korean headlines
No articles yet.